🚀 VC round data is live in beta, check it out!
Hisamitsu Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hisamitsu Pharmaceutical and similar public comparables like Celldex Therapeutics, Betta Pharmaceuticals, Soleno Therapeutics, Disc Medicine and more.
Hisamitsu Pharmaceutical Overview
About Hisamitsu Pharmaceutical
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
Founded
1944
HQ
Employees
3.7K
Website
Sectors
Financials (LTM)
EV
$2B
Hisamitsu Pharmaceutical Financials
Hisamitsu Pharmaceutical reported last 12-month revenue of $1B.
In the same LTM period, Hisamitsu Pharmaceutical generated $121M in net income.
Revenue (LTM)
Hisamitsu Pharmaceutical P&L
In the most recent fiscal year, Hisamitsu Pharmaceutical reported revenue of $980M and EBITDA of $220M.
Hisamitsu Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $980M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $573M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 58% | XXX | XXX | XXX |
| EBITDA | — | XXX | $220M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $121M | XXX | $137M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 14% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hisamitsu Pharmaceutical Stock Performance
Hisamitsu Pharmaceutical has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Hisamitsu Pharmaceutical's stock price is $37.97.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | -0.3% | XXX | XXX | XXX | $1.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHisamitsu Pharmaceutical Valuation Multiples
Hisamitsu Pharmaceutical trades at 1.9x EV/Revenue multiple, and 8.8x EV/EBITDA.
EV / Revenue (LTM)
Hisamitsu Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Hisamitsu Pharmaceutical has market cap of $3B and EV of $2B.
Equity research analysts estimate Hisamitsu Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hisamitsu Pharmaceutical has a P/E ratio of 22.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 8.8x | XXX | XXX | XXX |
| EV/EBIT | 17.2x | XXX | 16.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.4x | XXX | XXX | XXX |
| P/E | 22.1x | XXX | 19.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 62.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hisamitsu Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hisamitsu Pharmaceutical Margins & Growth Rates
Hisamitsu Pharmaceutical's revenue in the last fiscal year grew by 5%.
Hisamitsu Pharmaceutical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Hisamitsu Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hisamitsu Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hisamitsu Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Celldex Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Betta Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Soleno Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Disc Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Buchang Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hisamitsu Pharmaceutical M&A Activity
Hisamitsu Pharmaceutical acquired XXX companies to date.
Last acquisition by Hisamitsu Pharmaceutical was on XXXXXXXX, XXXXX. Hisamitsu Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hisamitsu Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHisamitsu Pharmaceutical Investment Activity
Hisamitsu Pharmaceutical invested in XXX companies to date.
Hisamitsu Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Hisamitsu Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hisamitsu Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hisamitsu Pharmaceutical
| When was Hisamitsu Pharmaceutical founded? | Hisamitsu Pharmaceutical was founded in 1944. |
| Where is Hisamitsu Pharmaceutical headquartered? | Hisamitsu Pharmaceutical is headquartered in Japan. |
| How many employees does Hisamitsu Pharmaceutical have? | As of today, Hisamitsu Pharmaceutical has over 3K employees. |
| Who is the CEO of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical's CEO is Kazuhide Nakatomi. |
| Is Hisamitsu Pharmaceutical publicly listed? | Yes, Hisamitsu Pharmaceutical is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical trades under 4530 ticker. |
| When did Hisamitsu Pharmaceutical go public? | Hisamitsu Pharmaceutical went public in 1962. |
| Who are competitors of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical main competitors are Celldex Therapeutics, Betta Pharmaceuticals, Soleno Therapeutics, Disc Medicine. |
| What is the current market cap of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical's current market cap is $3B. |
| What is the current revenue of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical's last 12 months revenue is $1B. |
| What is the current revenue growth of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical revenue growth (vs. last FY) is 5%. |
| What is the current EV/Revenue multiple of Hisamitsu Pharmaceutical? | Current revenue multiple of Hisamitsu Pharmaceutical is 1.9x. |
| Is Hisamitsu Pharmaceutical profitable? | Yes, Hisamitsu Pharmaceutical is net-income-positive (as of the last 12 months). |
| What is the current net income of Hisamitsu Pharmaceutical? | Hisamitsu Pharmaceutical's last 12 months net income is $121M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.